A detailed history of Jpmorgan Chase & CO transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 272,007 shares of ARCT stock, worth $4.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
272,007
Previous 317,551 14.34%
Holding current value
$4.85 Million
Previous $10.7 Million 38.24%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$24.35 - $44.39 $1.11 Million - $2.02 Million
-45,544 Reduced 14.34%
272,007 $6.62 Million
Q1 2024

May 10, 2024

SELL
$31.23 - $42.99 $164,519 - $226,471
-5,268 Reduced 1.63%
317,551 $10.7 Million
Q4 2023

Feb 12, 2024

SELL
$17.71 - $32.97 $85,539 - $159,245
-4,830 Reduced 1.47%
322,819 $10.2 Million
Q3 2023

Nov 14, 2023

SELL
$25.44 - $37.35 $276,609 - $406,106
-10,873 Reduced 3.21%
327,649 $8.37 Million
Q2 2023

Aug 11, 2023

SELL
$23.94 - $32.36 $79,432 - $107,370
-3,318 Reduced 0.97%
338,522 $9.71 Million
Q1 2023

May 18, 2023

BUY
$14.72 - $23.97 $260,617 - $424,388
17,705 Added 5.46%
341,840 $8.19 Million
Q1 2023

May 11, 2023

SELL
$14.72 - $23.97 $280,298 - $456,436
-19,042 Reduced 5.55%
324,135 $7.77 Million
Q4 2022

Feb 13, 2023

SELL
$14.14 - $23.06 $42,052 - $68,580
-2,974 Reduced 0.86%
343,177 $5.82 Million
Q3 2022

Nov 14, 2022

BUY
$13.05 - $22.13 $275,237 - $466,743
21,091 Added 6.49%
346,151 $5.13 Million
Q2 2022

Aug 11, 2022

SELL
$12.26 - $31.17 $919 - $2,337
-75 Reduced 0.02%
325,060 $5.12 Million
Q1 2022

May 11, 2022

SELL
$17.64 - $39.57 $519,356 - $1.17 Million
-29,442 Reduced 8.3%
325,135 $8.77 Million
Q4 2021

Feb 10, 2022

BUY
$34.2 - $47.56 $4.13 Million - $5.74 Million
120,744 Added 51.64%
354,577 $13.1 Million
Q3 2021

Nov 12, 2021

BUY
$27.88 - $58.25 $6.52 Million - $13.6 Million
233,833 New
233,833 $11.2 Million

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $474M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.